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Abstract
Background: Despite substantial investment in detection, early intervention and evidence-based treatments, current
management strategies for diabetes-associated retinopathy and cardiovascular disease are largely based on real-time
and face-to-face approaches. There are limited data re telehealth facilitation in type 2 diabetes management. Therefore,
we aim to investigate efficacy of telehealth facilitation of diabetes and cardiovascular disease care in high-risk
vulnerable Aboriginal and Torres Strait Islanders in remote/very remote Australia.
Methods: Using a pre-post intervention design, 600 Indigenous Australians with type 2 diabetes will be recruited from
three primary-care health-services in the Northern Territory. Diabetes status will be based on clinical records. There will
be four technological interventions: 1. Baseline retinal imaging [as a real-time patient education/engagement tool and
telehealth screening strategy]. 2. A lifestyle survey tool administered at ≈ 6-months. 3. At ≈ 6— and 18-months, an
electronic cardiovascular disease and diabetes decision-support tool based on current guidelines in the Standard
Treatment Manual of the Central Australian Rural Practitioner’s Association to generate clinical recommendations.
4. Mobile tablet technology developed to enhance participant engagement in self-management. Data will
include: Pre-intervention clinical and encounter-history data, baseline retinopathy status, decision-support and
survey data/opportunistic mobile tablet encounter data. The primary outcome is increased participant adherence
to clinical appointments, a marker of engagement and self-management. A cost-benefit analysis will be performed.
Discussion: Remoteness is a major barrier to provision and uptake of best-practice chronic disease management.
Telehealth, beyond videoconferencing of consultations, could facilitate evidence-based management of diabetes and
cardiovascular disease in Indigenous Australians and serve as a model for other conditions.
Trial registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ACTRN 12616000370404 was
retrospectively registered on 22/03/2016
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Background
Diabetes and cardiovascular disease (CVD) are leading
causes of personal and healthcare system disease bur-
den, globally [1], and in Australia [2]. It is anticipated
that this burden will disproportionately affect vulner-
able populations, such as those in low-income countries
and Indigenous populations [3], particularly in remote
settings.
A wide range of interventions aimed at improving
chronic disease outcomes and reducing care costs has
been tried. These interventions mostly fall into one of
two categories. One aspect is quality-improvement that
focuses on service delivery in primary care and support
services for patient self-management. The other aspect
is patient-based disease-management. Evidence suggests
the interventions that not only target disease manage-
ment, but also aim to improve care-delivery design may
be more effective than those that target disease man-
agement alone [4, 5]. Targeted e-health applications
that facilitate both service delivery and disease manage-
ment have potential to meet such an objective. To date,
clinical e-health applications mainly relate to the use of
electronic health record systems (often alongside older
paper-based systems), telecommunication of medical
reports and videoconferencing consultations between a
clinician and patient.
Telehealth is, in the context of the present study, that
area of e-health that centres on the provision of health-
related services and information using telecommunication-
based technologies. Telehealth in the clinical setting is in its
infancy in Australia [6], where the use of this term has been
largely limited to one Federal government funded health-
related service — that of a videoconferencing consultation
between a specialist clinician and patient, subject to
specific criteria [7]. By contrast, global uptake of a
broad spectrum of e-health technologies, particularly
mobile-health, is high [8].
Telehealth facilitation of service delivery and disease
management has the potential to improve health out-
comes for people with diabetes and to improve the
quality of service delivery in the primary care setting.
Currently, there are inadequate data to support the
widespread clinical uptake of telehealth technologies.
Therefore, the ‘Telehealth Eye and Associated Medical
Services Network’ [TEAMSnet] study aims to address
the knowledge gaps in three areas — telehealth
facilitation of 1. diabetic retinopathy screening 2.
evidence-based diabetes and CVD management (via
decision support and survey tools) and 3. patient
self-management strategies.
This paper presents the protocol for the TEAMSnet
study. This technology-based pre-post intervention study
aims to describe the baseline characteristics of the par-
ticipants with diabetes and clinical workflows in partner
health service and to investigate the impact of telehealth
facilitation in the management of CVD, diabetes and
diabetic retinopathy. We hypothesise that telehealth
facilitation of diabetes management will lead to improve-
ments in patient engagement [attendance rates and
survey participation] and clinical outcomes, such as
blood pressure and metabolic control.
Methods/Design
Study design
This is a pre-post study of technology-facilitated man-
agement of diabetes, CVD, and diabetic retinopathy.
We plan to enrol 600 adults (age ≥18 years) with clinic-
ally-diagnosed diabetes from three remote Northern Ter-
ritory Aboriginal-controlled health services — Central
Australian Aboriginal Congress [CAAC] in Alice Springs,
Miwatj Health Aboriginal Corporation [Miwatj] that in-
corporates the four clinics at Nhulunbuy, Galiwin’ku/
Elcho Island, Yirrkala, Gunyangara/Ski Beach in East
Arnhem Land and Wurli-Wurlinjang Health Service
[Wurli] in Katherine. Recruitment and intervention are
anticipated to occur over a 3-year period. Participants
will receive retinal imaging, diabetic retinopathy
screening, including diabetes education, at baseline,
followed by lifestyle assessment six months later, in-
cluding self-management support. An electronic CVD
and diabetes decision support tool that includes an
Indigenous-specific CVD risk calculator, based on best-
practice as generally defined by guidelines in the
current Standard Treatment Manual of the Central
Australian Rural Practitioner’s Association [CARPA],
will be developed in conjunction with a clinical working
group and used to generate a clinical recommendations
report to assist clinicians with evidence-based manage-
ment of CVD, diabetes and diabetic retinopathy
approximately 6–18 months after baseline. Mobile tab-
let technology based on clinical input and feedback will
be developed to support clinical staff and participants
with engagement in diabetes management and self-
management, respectively.
Study aims and objectives
The overarching aim of the TEAMSnet project is to
improve health care, and therefore health outcomes,
for Indigenous Australians in under-resourced commu-
nities through the integration of existing electronic
health record systems, specifically Communicare™
(Healthconnex, Perth, Australia), with the customis-
able, web-based health information technology called
Chronic Disease Management Platform [CDMP], an
existing, licence-free platform that thereby facilitates
sustainability. A secondary aim is to evaluate the cost-
efficacy of the intervention. There are three main ob-
jectives under the broad aim.
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1. Telehealth facilitation of clinical management via
CVD and diabetes electronic decision support and
remote image-based diabetic retinopathy assessment
Our first objective is to make it easier for treating
doctors to adhere to relevant evidence-based
guidelines, specifically the current Standard
Treatment Manual of the Central Australian Rural
Practitioner’s Association (CARPA) [9] and the
2008 NHMRC Guidelines for the Management
of Diabetic Retinopathy [10], prepared by the
Australian Diabetes Society. To this end, (1) CARPA
guidelines are being encoded into a CARPA_CVD
and diabetes electronic decision support application
[EDS] that sits within CDMP. In addition, evidence-
based diabetic retinopathy management has been
made easier for primary care practitioners via (2)
the development of a second application, Global
Retinal Imaging [GRI], that interfaces with the
widely–used Centervue DRS and Canon CR-2
non-mydriatic retinal cameras and stores the
captured digital retinal and external eye images.
These imaging, grading and reporting data are
accessible from within CDMP to both certified
retinopathy graders [for grading diabetic retinopathy
level and generating retinopathy reports based on
2008 Australian NHMRC diabetic retinopathy
management guidelines] and to authorized medical
and eyecare practitioners [to view and compare
ocular images and retinal status over time, thereby
facilitating continuity of care].
2. CDMP-based facilitation of shared clinical
information, such as login access to CDMP-stored
retinal images for ophthalmologists and optometrists
Our second objective is to improve the timely
exchange of relevant health information and the
communication between a patient’s health care
providers. CDMP facilitates this through use of
a unique practitioner access code that enables a
specialist medical practitioner, such as an
optometrist or ophthalmologist, to view only
relevant patient data, including reports.
3. Improve engagement of patients in self-care,
particularly adherence to clinical visits
Our third objective is to improve engagement
of patients in self-care. GRI retinal imaging will
provide both a powerful education and retinopathy
assessment opportunity. In addition, a third technology,
(3) a custom-built e-mobile health device in the form
of a tablet with viewable clinical data, GRI images
and educational content, developed with clinical
and Aboriginal Health Worker input, will facilitate
health worker communication with patients
between medical consultations and is aimed at
improving relationships and engaging patients in
self-care. A fourth application, (4) a suite of
lifestyle surveys and a related reporting template
based on CARPA recommendations for smoking,
nutrition, alcohol, physical activity and emotional
well-being [SNAPE] has been developed and is
accessible via CDMP in a clinical setting or via
the mobile tablet application anywhere. This is
designed to be both a patient engagement and
clinical management tool that facilitates the
measurement, goal-setting and monitoring of
important lifestyle risk factors for CVD, diabetes
and diabetic retinopathy. All three telehealth
reports, EDS, GRI and SNAPE, will be accessible
via either the EHR [Communicare] or CDMP.
Apart from the development and implementation of
the four technologies, the primary outcome includes im-
proved adherence to clinical care, such as eyecare visits.
Secondary outcomes include reduction in hospitaliza-
tions and cost-efficacy of the suite of technologies, both
individually and collectively.
Site recruitment
An invitation was circulated to Aboriginal-Controlled
Community Health Organizations [ACCHO] in the
Northern Territory to attend an information work-
shop at the Alice Springs Hospital. Following this, an
expression of interest was sought from attendees. A
discussion paper was circulated for internal discus-
sions within the health service to the three health ser-
vices that formally expressed an interest in the
project. Once health service board approval had been
obtained, a formal letter of support from the health
service for the TEAMSnet study was sought and
Memoranda of Understanding and service agreements
were executed between partner sites and the adminis-
tering institutions, the Universities of Melbourne and
Sydney. Ethics applications were submitted by investi-
gators to the Central Australian and Menzies School
of Health Research Human Research Ethics Commit-
tees. Recruitment commenced once written ethics ap-
proval had been obtained.
Participant eligibility
Inclusion criteria
Participants must be clients of the partner health ser-
vices who are aged 18 or over; can provide informed
consent; can successfully undergo retinal imaging; are
willing to undertake surveys and provide relevant
clinical information; and are willing to consult their
doctor on at least two occasions over the following
18 months.
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Exclusion criteria
Clients of the partner health services are ineligible if
they been clients for less than six months prior to en-
rollment or have had diabetic retinopathy treatment.
Sample recruitment
Both community-based and direct recruitment strategies
are being used to recruit study participants. These in-
clude; flyers in medical waiting and consulting rooms,
and contact with potential referral sources, for example,
general practitioners, chronic care team members —
podiatrist, dietitian, cardiac nurse, renal nurse, diabetes
educator, text and letter invitations.
Prospective participants express their interest to the
study co-ordinator at a face-to face meeting during
which the individual is screened. If the individual meets
the inclusion criteria, they are consented to the study
(consent form signed after patient information sheet dis-
cussed) and diabetic retinopathy screening is performed
(baseline visit) in order to reduce the time burden on




1. Baseline visit — Retinal imaging-based diabetic
retinopathy screening
Imaging of participants by TEAMSnet trained
clinic staff aims to provide a valuable patient
education and engagement opportunity in addition
to facilitating the timely detection of diabetic
retinopathy.
Our diabetic retinopathy screening method is
based on a protocol developed in collaboration
with the Joslin Diabetes Centre in the USA. Key
features are — (1) Digital Imaging and
Communications in Medicine (DICOM) compliant
images from digital non-mydriatic retinal fundus
cameras are cached or transmitted over the internet
using Transport Layer Security [TLS] encryption
[based on connectivity] via the GRI application
to a remote grader. (2) Grading and reporting to
Communicare at the originating site is completed
within two working days of the grading centre
receiving the imaging studies that can be viewed
as an active work list on the grader’s computer
system. (3) Images can be viewed anytime,
anywhere in the web-based CDMP application
by clinic-authorized personnel. Optometrists,
ophthalmologists, primary care doctors, endocrinol-
ogists, nurses, health workers and retinal imagers
will be provided with filtered levels of information
via a unique access code.
The main elements of the retinal imaging protocol
are —
(1) History — Patient demographic data are entered.
Presenting vision is recorded [pinhole if below
6/6 when possible], either unaided or aided by
spectacles. If presenting vision is unaided, but
patient has distance vision spectacles, then acuity
with spectacles is also recorded. Date of last eye
exam or any significant ocular history [surgery,
trauma] is noted electronically in the GRI intake
template text field.
(2) Preparation for imaging — Dilating drops
[one each of 1% tropicamide and 2.5%
phenylephrine] are instilled, unless
contraindicated or patient refuses permission
to instil drops, and the patient waits for 15 min
or until the pupil diameters are at least 4 mm.
We use the waiting time of 15 min to discuss
the appearance of a normal retinal and the value
of retinal imaging as a window into vascular
health. In the absence of pupil dilation and
before being imaged the patient requires five
minutes [minimum] of dark adaptation in a
windowless or pitch black room in order to
maximize pupil size.
(3) Imaging sequence — a total of 6 images per eye
are acquired, two macula-centred [stereo] fields
are imaged first for each eye. The disc-centred
field is the third field to be imaged [for vessel
calibre and disc assessment]. The nasal and
superior-temporal fields for documenting diabetic
retinopathy and other findings are the fourth and
fifth retinal fields, respectively. The sixth field is
the anterior eye/external field for documentation
of ocular surface and lid pathology and for future
patient identification (Fig. 1).
(4) Camera maintenance — Procedures for camera
start up, close down, lens cleaning, storage and
syncing with the GRI application have been
documented for use by site staff.
Key elements of the diabetic retinopathy grading
protocol are as follows —
(1) Grading of retinopathy and vessel calibre
measurements are being undertaken by Centre
for Eye Research Australia [CERA]-certified
graders at the Royal Victorian Eye and Ear
Hospital, Australia [RVEEH] grading centre,
with ophthalmological adjudication as required.
(2) Images are first read for presence and extent of
retinal pathologic lesions (haemorrhages and
microaneurysms, venous beading etc.) i.e. number
of specific lesions per retinal quadrant per image
per eye are documented electronically according
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Fig. 1 Diabetic Retinopathy Screening imaging fields
Fig. 2 Diabetic Retinopathy Screening referral protocol
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to the Early Treatment Diabetic Retinopathy
Study standardised grading protocol. A
grading algorithm based on the Early
Treatment Diabetic Retinopathy Study
[ETDRS] classification of diabetic retinopathy
analyses the electronically-entered retinal
lesion data automatically calculates a preliminary
clinical level of diabetic retinopathy. This
initial grading is either accepted or modified
by a grader after comparison with the relevant
ETDRS standard field.
(3) The referral protocol (Fig. 2) is based on the
2008 NHMRC Guidelines for the Management
of Diabetic Retinopathy.
(4) The reporting protocol (Fig. 3) has been
developed with a view to highlighting the
essential management recommendation in the
TEAMSnet retinopathy screening report that is
sent to Communicare at the participating site via
Argus messaging (a third party vendor providing
secure communications between health services)
for the primary care health professional to
Fig. 3 Diabetic Retinopathy Screening reporting protocol
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evaluate and action in the context of the
participant’s prior ocular history in the EHR [as is
the case with pathology reports].
(5) Subsequently, the disc-centred images in a spe-
cific format will be used by graders for retinal
vessel calibre measurements, which have been
shown to predict CVD and retinopathy onset and
progression (Fig. 4) [11, 12].
2. SNAPE lifestyle survey development, administration,
reporting and referral protocols
Validated surveys for smoking, alcohol, physical
activity and emotional wellbeing/depression have
been codified into a survey tool for online use via
CDMP or mobile tablet login. For offline use a
print copy of the SNAPE survey reporting template
can be used. A relevant and validated nutrition
survey is not available so experienced research
nutritionists and clinicians have developed a brief
diet quality questionnaire adapted from recent
studies in Indigenous health.
Trained study staff will administer the suite
of surveys during the second study visit some
6- months after the imaging visit. The SNAPE
report (Fig. 5) can be viewed either in the EHR
systems (within 24 h) or immediately via login to
CDMP or the mobile tablet. The primary care
clinician upon review of the report will generate a
referral as indicated. High depression scores are
brought to the immediate attention of the
participant’s treating clinician. Participants’
comments around goals and barriers/motivators
to change, such as food security (access to healthy
food), will be documented by the survey
administrator.
3. EDS development, use and reporting protocol
Once partner sites were identified, we identified
the CARPA standard treatment manual as the most
appropriate guideline for CVD and diabetes EDS
development. As Communicare is the EHR system
used by all partner sites, ideally the TEAMSnet
EDS application would need to be interfaced with
Communicare for automated syncing of as much
of the clinical data required by EDS as possible so as
to avoid duplication and improve clinical efficiency.
The developers of the CARPA standard treatment
manual and Communicare were advised of the
TEAMSnet project and agreed to support the
project informally as advisors and collaborators,
particularly in relation to timing of their product
updates and releases. In return, TEAMSnet would
provide both organisations with potentially useful
user feedback during the project.
TEAMSnet EDS will provide clinicians with three
CVD and diabetes management tools.
(1) The CVD risk calculator and slide rule that enables
baseline measurement and regular monitoring of a
participant’s overall CVD risk (Fig. 6).
(2) The detailed CVD and diabetes risk-analysis tool
that provides a clinician with specific
recommendations and optional learning points
for best-practice management of a participant’s
CVD risk (Fig. 7).
(3) Active CVD and diabetes decision-support tool
— a proactive clinical process whereby each
recommendation is reviewed by the clinician
and either accepted or rejected, in which
case a textbox appears for the explanation.
An EDS report will be generated for each
participant as soon as possible after the s
econd clinical visit [at which surveys are
administered]. A second and final EDS report
will be generated for participants prior to the
end of the study (Fig. 8).
4. Mobile tablet application
Mobile tablet development and use will
enable display and review of much of the
data derived from GRI, SNAPE surveys and EDS
applications. Surveys can be administered and
an educational resource library can be populated
and accessed via the tablet, and this can take
place in an out-of-clinic setting, thereby
facilitating patient engagement.
Fig. 4 Retinal vessels used for calibre measurement protocol
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Data collection and outcome measures
Demographic data (including age, gender, postcode, con-
tact details) and self-report measures are obtained from
each participant at baseline and/or at the 6-month survey
administration visit. Pre- and post-study clinical data such
as blood and urine biochemistry, blood pressure and an-
thropometric measures including height and weight are
also collected. Pre- and post-study health care resource
utilization is captured through EHR records and includes
information on hospitalizations and eye-care consultations.
Pre-study data
Site partners will collaborate to audit the Communicare
EHR for each participant in order to obtain the required
pre-study data i.e. the data that correspond with post-study
data relating to CVD, diabetes or diabetic retinopathy risk
and outcomes and each participant’s use of health services,
such as eye-care consultations and hospitalizations.
Data management
The study coordinators at respective sites will be respon-
sible for electronic scanning and storage of hard copies
of participant consent and report forms for entry into
the password protected central database. Hard copies
will be kept in a secure cabinet at the respective sites. If
requested, participants can access their individual results
at study completion.
Fig. 5 SNAPE lifestyle survey report
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Study integrity
Approval to conduct the study was received from Cen-
tral Australian and Menzies School of Health Research
Human Research Ethics Committees in the Northern
Territory. Written informed consent will be obtained
from all participants. A local translator will assist in con-
senting patients for whom English is not their first
language.
Sample Size
For a conservative differential in adherence to subse-
quent care of 15%, and with 80% power, the minimum
sample required is 490. Estimates are based on a 25%
attrition rate. We will therefore need 600 participants
across the three partner sites.
Data analysis
Investigators and their supporting statistics departments
will conduct data analysis. Site differences will be ana-
lysed. Analyses will provide important descriptive data,
such as prevalence rates and lifestyle data, proportion
treated to target for CVD, diabetes and diabetic retinopathy
risk factors and predictors of diabetic retinopathy and CVD
outcomes. Analysis of covariance (ANCOVA) will be used
to compare differences between groups. To assess con-
founding, covariates will include age, gender, and
Fig. 6 CARPA-designated risk analysis inputs
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established and emerging risk factors for CVD, diabetes
and diabetic retinopathy, as appropriate. Non-parametric
statistics will be used when assumptions for parametric
methods are violated. All tests will be conducted using an
alpha level of 0.05 and 95% confidence intervals will be
reported.
Complete case analysis and, where reasonable, mul-
tiple imputation will be employed for the manage-
ment of missing data. Missing data may occur due to
drop-out, missed assessments or item non-response.
With knowledge of the missing data mechanism, all
available information can be used. One approach will
be to use the multilevel model, a full-likelihood
method that allows for a response to be missing at
random, where missingness depends only on observed
data and not on unobserved data. Another strategy in-
volves imputing missing values by multiple imput-
ation procedures.
The proposed economic evaluation aims to include
pre- and post-study resource utilization costs for both
the costs and consequences and a cost consequence ana-
lysis (CCA). Standard unit costs i.e. Australian Medicare
Benefits Schedule will be applied to the resource-use
data. Costs will be presented in total and disaggregated
Fig. 7 CARPA-based risk analysis report
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forms, such as those from different sectors — the health
sector, patients and government.
Of the recruitment target of 600 Indigenous Austra-
lians with diabetes, to date 576 participants have been
recruited and undergone retinal imaging for diabetic ret-
inopathy screening.
Discussion
It is well-known that a significant number of individuals
with diabetes fail to adhere to screening recommenda-
tions and/or adequately self-manage diabetes-related risk
factors and consequences. Furthermore, primary care
service delivery for diabetes and its complications is
challenging, even in well-resourced environments with a
large proportion of patients at low risk of diabetes com-
plications and related conditions, such as depression.
Importantly, the disease burden of diabetes in Australia
is greatest amongst Indigenous Australians, particularly
in remote settings.
Telehealth facilitation of service delivery and diabetes
management has potential benefits. To date, there are
insufficient data to answer the question ‘Can telehealth
applications facilitate best-practice in diabetes and CVD
service delivery and disease management in remote
Fig. 8 CARPA-based EDS report with accepted and rejected risk analysis recommendations
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Indigenous Australian communities?’ The TEAMSnet
study will provide evidence regarding the efficacy and
cost-efficacy of telehealth facilitation in the management
of diabetes, its complications and related conditions in
remote and very remote Indigenous Australian commu-
nities. We anticipate benefits in the area of new and
modified diabetes management strategies alongside im-
provements in patient self-management.
This multi-pronged telehealth approach may facilitate
the management of diabetes, an increasingly prevalent
and complex chronic condition and public health prob-
lem. The benefits of telehealth facilitation of retinal
screening, lifestyle modification and electronic decision
support might then be extended to other complications
of diabetes and common co-morbidities.
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